Price T Rowe Associates Inc Alkermes Plc. Transaction History

Price T Rowe Associates Inc

  • $883 Billion
  • Q2 2025

A detailed history of Price T Rowe Associates Inc transactions in Alkermes Plc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 10,041,900 shares of ALKS stock, worth $275 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
10,041,900
Previous 11,788,245 14.81%
Holding current value
$275 Million
Previous $389 Million 26.19%
% of portfolio
0.03%
Previous 0.05%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025
SELL
$26.59 - $32.65 $46.4 Million - $57 Million
-1,746,345 Reduced 14.81%
10,041,900 $287 Million
Q1 2025

May 14, 2025
SELL
$28.08 - $36.0 $13.1 Million - $16.9 Million
-468,202 Reduced 3.82%
11,788,245 $389 Million
Q4 2024

Feb 14, 2025
SELL
$25.7 - $31.46 $19.1 Million - $23.3 Million
-742,159 Reduced 5.71%
12,256,447 $352 Million
Q3 2024

Nov 14, 2024
BUY
$23.01 - $28.55 $45.7 Million - $56.7 Million
1,986,294 Added 18.04%
12,998,606 $364 Million
Q2 2024

Aug 14, 2024
BUY
$23.21 - $27.24 $62.3 Million - $73.2 Million
2,686,056 Added 32.26%
11,012,312 $265 Million
Q1 2024

May 15, 2024
BUY
$26.4 - $32.56 $178 Million - $219 Million
6,730,671 Added 421.83%
8,326,256 $225 Million
Q4 2023

Feb 14, 2024
BUY
$23.37 - $28.68 $1.76 Million - $2.15 Million
75,100 Added 4.94%
1,595,585 $44.3 Million
Q3 2023

Nov 14, 2023
BUY
$27.17 - $31.97 $299,929 - $352,916
11,039 Added 0.73%
1,520,485 $42.6 Million
Q2 2023

Aug 14, 2023
SELL
$28.34 - $33.63 $960,867 - $1.14 Million
-33,905 Reduced 2.2%
1,509,446 $47.2 Million
Q1 2023

May 15, 2023
SELL
$25.31 - $29.02 $682,408 - $782,437
-26,962 Reduced 1.72%
1,543,351 $43.5 Million
Q4 2022

Feb 14, 2023
SELL
$21.94 - $26.24 $68.4 Million - $81.8 Million
-3,116,858 Reduced 66.5%
1,570,313 $41 Million
Q3 2022

Nov 14, 2022
SELL
$22.0 - $31.87 $127 Million - $183 Million
-5,752,767 Reduced 55.1%
4,687,171 $105 Million
Q2 2022

Aug 15, 2022
SELL
$26.4 - $30.54 $279 Million - $323 Million
-10,560,157 Reduced 50.29%
10,439,938 $311 Million
Q1 2022

May 16, 2022
SELL
$23.07 - $27.99 $7.92 Million - $9.61 Million
-343,486 Reduced 1.61%
21,000,095 $553 Million
Q4 2021

Feb 14, 2022
BUY
$21.47 - $32.08 $1.66 Million - $2.48 Million
77,340 Added 0.36%
21,343,581 $496 Million
Q3 2021

Nov 15, 2021
SELL
$23.37 - $32.13 $36.9 Million - $50.7 Million
-1,578,713 Reduced 6.91%
21,266,241 $656 Million
Q2 2021

Aug 16, 2021
SELL
$18.78 - $25.15 $17.1 Million - $22.9 Million
-909,684 Reduced 3.83%
22,844,954 $560 Million
Q1 2021

May 17, 2021
BUY
$18.21 - $23.2 $3.24 Million - $4.12 Million
177,736 Added 0.75%
23,754,638 $444 Million
Q4 2020

Feb 16, 2021
BUY
$15.39 - $22.1 $363 Million - $521 Million
23,576,902 New
23,576,902 $470 Million

Others Institutions Holding ALKS

# of Institutions
394
Shares Held
176M
Call Options Held
558K
Put Options Held
427K
View Full List

About Alkermes plc.

ALKS Quotes by TradingView
  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.49B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email